Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers.
Authors: Hamid O, Forget F, Johnson M, George TJ, Bourayou N, Ioannidis S, Zhou F, Yang H, Dong Z, Gutierrez ME
Journal: The oncologist
acceptance commitment therapy
mental health
open access